Navigation Links
Watson Confirms Crestor® Patent Challenge
Date:10/27/2010

MORRISTOWN, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed a new drug application under Section 505(b)(2) of the Federal Food and Drug Cosmetic Act (FFDCA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rosuvastatin zinc 5, 10, 20 and 40 mg tablets.  Watson's rosuvastatin zinc tablets are a new salt version of AstraZeneca's Crestor ® tablets.  Crestor® is indicated, as an adjunct to diet, to lower LDL cholesterol, raise HDL cholesterol, and slow the progression of atherosclerosis.

AstraZeneca filed suit against Watson on October 26, 2010 in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. RE 37,314.  AstraZeneca's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's NDA until March 30, 2013 or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

For the twelve months ending June 30, 2010, Crestor ® had total U.S. sales of approximately $3.5 billion according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watsons Generic Version of Lotrel ® Receives FDA Approval
2. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings
3. Watson Reaches Settlement with Endo Over Opana® ER
4. Watson Confirms Azilect® Patent Challenge
5. Watson to Present at the Jefferies 2010 Global SpecPharma & European Healthcare Conference
6. HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada
7. Watson to Present at the Bank of America/Merrill Lynch Global Healthcare Conference
8. Watsons Generic Yasmin® Receives FDA Approval
9. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
10. Watson Promotes Robert Stewart to Executive Vice President, Global Operations
11. Watson Confirms Renvela® for Oral Suspension Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... holística de l cuidado al paciente ... trayecto   Royal Philips  ... europeo de IntelliSpace Cardiovascular , un sistema web ... herramientas para acceder, analizar y compartir imágenes cardiovasculares e ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
... Caliper Life Sciences, Inc. (Nasdaq: ... and services for drug discovery and life sciences ... Austria AG for the co-development and manufacture of ... The agreement combines Sony DADC,s premier Blu-ray Disc™ ...
... Nov. 3, 2010 Cyberonics, Inc. (Nasdaq: CYBX ) ... second quarter ended October 29, 2010 of its fiscal year ending ... ET.  The company will conduct a conference call to discuss those ... Fiscal Year 2011 Second Quarter Results Conference Call InstructionsTo ...
Cached Medicine Technology:Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results 2
(Date:9/1/2015)... Knoxville, TN (PRWEB) , ... September 01, 2015 ... ... allow users to send information about new patients directly from Practice Perfect to ... and duplicate data entry. , Steven Presement, President of Practice ...
(Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and voice ... There are over 100 different types of arthritis. One of the most popular is ... to shed light on this important topic. , Anyone who is nearing their golden ...
(Date:9/1/2015)... Toronto, ON (PRWEB) , ... September 01, 2015 ... ... Trade Secrets, a leading retailer of professional hair salons. This highly anticipated partnership ... all of the Curl Keeper™ Styling Collection. Founder Jonathan Torch and the Curly ...
(Date:8/31/2015)... ... 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics proudly announces that Kathy ... by Modern Luxury’s The Atlantan Magazine. , This award for the Sculpted ... Her idea and vision to bring to Atlanta a true luxury experience in ...
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... When it comes to ... scalp to the top of the head. Adding more volume to the hair on ... simple procedure for patients who have a good amount of donor hair on other areas ...
Breaking Medicine News(10 mins):Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:Curly Hair Solutions™ Partners With Trade Secrets 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 2Health News:Sculpted Contours Owner Selected One of Atlanta's Women of Power and Influence by Modern Luxury's The Atlantan Magazine 3Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2
... the first-ever signs of a drop in new HIV ... with the world's second-heaviest AIDS burden. ... prevalence among pregnant women had dropped to 29.1 percent ... Tshabalala-Msimang told journalists in Pretoria. ,"The report ...
... the rim of one of the most active volcanoes in ... government regulators . ,A South Korean group, Jung ... a 72 million-peso (1.57 million-dollar) spa-resort on Taal volcano south ... ,Unless the company fulfils the demands by Thursday ...
... developed a new technique to diagnose mad cow disease ... University say that the currently available screening process for ... specialists to wrongly tell people that they are suffering ... that the new technique developed by them can detect ...
... at Imperial College London have found that injections of ... the lives of children with brittle bone disease , ... in human foetuses by DNA testing or ultrasound, disrupts ... Those with the condition suffer fractures while in the ...
... Company and the Phoenix-based Translational Genomics Research Institute ... alter tumour cell proliferation, and make them resistant to ... that they found a recurring mutation of the gene ... ,The AKT pathway is among the most commonly ...
... on Economic Affairs (CCEA) today gave its approval for ... (RNTCP) for five years - - from April 2007 ... Chhattisgarh, Jharkhand and Uttranchal. ,The CCEA also gave ... - - Andhra Pradesh, Chandigarh, Haryana, Maharashtra, Punjab and ...
Cached Medicine News:Health News:Furore Over Spa Planned on Active Philippines Volcano 2Health News:Genetic Mutation That Makes Common Cancers Resistant to Drugs Identified 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This instrument can be used as a spoon forceps in gynecologic surgery....
This is a single-action instrument that features a spring handle....
Medicine Products: